THERAVECTYS
THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions..
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | €16.5m | Late VC |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 93 % | 1224 % | (97 %) | (100 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1634 %) | (831 %) | - | (3040 %) | (6093389 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (2172 %) | (378 %) | 15 % | (3284 %) | (5784295 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Theravectys operates in the biotech sector, focusing on the development of T cell vaccines using a proprietary lentiviral vector platform. The company targets both prophylactic and therapeutic vaccines, addressing critical unmet medical needs such as chronic infections and cancers, including the global HIV epidemic. By leveraging over 20 years of research, Theravectys aims to transform the field of vaccinology through strategic industrial partnerships and collaborations, including a joint laboratory with the Pasteur Institute. The business model centers on preclinical proof of concept across a broad range of indications, moving products through clinical stages and regulatory approval. Revenue is generated through global licensing and partnerships, positioning Theravectys as a potential game-changer in global health. Keywords: lentiviral vectors, T cell vaccines, chronic infections, cancers, HIV, biotech, partnerships, clinical trials, global health, licensing.